...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Primary Endpoint Results for Phase 3 BETonMACE Cardio Outcomes Trial were Announced September 30th ****Detailed Trial Data to be Presented at AHA Late Breaking Session Nov 16th & Company Webcast Nov 18th******

Message: Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019

Thanks BDZ,... that symposium sounds super interesting,... is that a sign of confidence,... ?

Any chance they will announce TLD here,... if we met Primary Endpoint,...?


New Message
Please login to post a reply